Introduction: Lung cancer is the leading cause of cancer death in men and women, and current second-line chemotherapy regimens yield relatively poor response and survival rates. Hypothesis: We hypothesized that the combination of weekly docetaxel (D) and gemcitabine (G) would show activity in the second-line setting. We therefore conducted a phase II trial evaluating this regimen in patients with relapsed or progressive non-small cell lung cancer (NSCLC) after first-line platinum-based therapy. Methods: Patients with recurrent NSCLC, adequate physiologic indices, and exposure to one prior platinum-based regimen were eligible. Docetaxel 40 mg/m 2 intravenous (IV) and gemcitabine (G) 800 mg/m
L
ung cancer is the leading cause of cancer-related death in men and women. The American Cancer Society has estimated that the number of new lung cancer cases in the United States will be 114,690 in men and 100,330 in women for 2008. Among them, 161,840 are expected to die from this disease. Treatment of advanced stage lung cancer is evolving, with the development of new biologic therapies, such as erlotinib and bevacizumab, adding to the therapeutic arsenal, both in the first and second line. Nevertheless, a platinum-based doublet is still the cornerstone of first-line therapy in non-small cell lung cancer. The estimated 1-year survival with a platinum-based doublet is approximately 30 to 35% 1 and median time to progression remains poor at about 3 months. Second-line therapy is indicated at the time of progression in patients with good performance status, and it has become the standard of care in non-small cell lung cancer patients who have experienced disease progression after first-line therapy.
Docetaxel has had an established role as second-line therapy for nearly a decade. Based on two separate phase III trials that showed a survival advantage compared with either best supportive care (BSC) or to ifosfamide or vinorelbine, it was the first Food and Drug Administration-approved agent for salvage therapy in the United States. A study by Shepherd et al. 2 using single agent docetaxel showed time to progression of 10.6 weeks compared with 6.7 weeks in the BSC control group in patients with recurrent lung cancer with a threefold improvement in 1-year survival rate for the docetaxel group (37%) compared with the BSC group (11%). A second trial by Fossella et al. 3 demonstrated no difference in median survival times, but a 10% improvement in 1-year survival rate for docetaxel 75 mg/m 2 compared with either ifosfamide or vinorelbine. Weekly docetaxel has resulted in similar efficacy compared with a conventional every 3-week schedule with improved toxicity profile. 4 A subsequent study in chemotherapy-naive lung cancer patients using docetaxel and cisplatin treatment resulted in response rate (RR) of 31.6% and median survival of 11.3 months compared with RR of 24.5% and median survival of 10.1 month in the vinorelbine and cisplatin control arm. 5 Before the recent approvals of Erlotinib and Pemetrexed as single agents in 2004 for second-line treatment, gemcitabine seemed to be an equally promising agent in this setting. A nonplatinum doublet of docetaxel and gemcitabine constituted a logical choice for investigation in the secondline setting after prior use of platinum.
Gemcitabine is a nucleoside analog, initially tested in lung cancer as first-line therapy. Single agent gemcitabine in phase II trials resulted in RRs of 20% and median survival of 7 months. 6, 7 Combination of gemcitabine and cisplatin generated a RR of 30.4% and a median survival of 9.1 month, 8 and proved superior to cisplatin alone, yielding FDA approval for gemcitabine with cisplatin in the frontline therapy for non-small cell lung cancer (NSCLC).
The combination of docetaxel with gemcitabine has shown promising results as first-line therapy. Phase I/II trials established the respective maximum tolerated dose of docetaxel weekly at 36 to 50 mg/m 2 and gemcitabine at 800 mg/m 2 to 1000 mg/m 2 on day 1 and 8. 9, 10 Other studies employed docetaxel at a bolus dose on day 1 of a 3-week schedule with maximum tolerated dose of 60 mg/m 2 to 80 mg/m 2 . 11, 12 Phase II trials yielded promising activity for this combination in NSCLC, 13, 14 and a subsequent phase III trial using this regimen comparing it with other platinum doublets showed equivalent RR and reduced toxicity. 15 Human epidermal receptor 2 (HER-2) is an important prognostic marker in breast cancer. 16 HER-2 is also expressed in lung cancer 17 and its overexpression is associated with shorter survival. 18 The monoclonal antibody trastuzumab binds specifically to HER-2, and when combined with chemotherapy, it has demonstrated significantly greater efficacy compared with chemotherapy alone in patients with metastatic breast cancer. 19 Given the potential synergistic effect, studies have been devised incorporating the use of trastuzumab with chemotherapy in the treatment of advanced lung cancer. Phase II trials testing the combination of trastuzumab with standard chemotherapy in non-small cell lung cancer showed feasibility for this approach with median and 1-year survival rates matching or exceeding prior results in the absence of trastuzumab. 20, 21 Our intention was to graft this agent onto combination of weekly gemcitabine and docetaxel in the secondline setting, but we aborted this effort when the first 18 enrollees tested negative for HER-2-neu by either fluorescence in situ hybridization or immunohistochemistry. Hence, we restricted our phase II study to the cytotoxic combination, testing this nonplatinum doublet in recurrent lung cancer patients. The primary endpoint was RR; secondary endpoints included survival and event-free survival (EFS).
PATIENTS AND METHODS
Second-line patients with advanced NSCLC and prior platinum exposure received combination of gemcitabine and docetaxel on a weekly basis. Eligibility stipulated pathologically diagnosed non-small cell lung cancer; progressive disease after initial platinum-based chemotherapy with at least a 28 day chemotherapy hiatus; Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; no active brain metastases (not on steroids and stable clinically after radiation); expected survival of more than 6 months; and no other concurrent invasive malignancies.
Treatment Plan
The treatment regimen consisted of docetaxel weekly at 40 mg/m 2 and gemcitabine at 800 mg/m 2 day 1 and 8 every 21 days. Patients with a history of prior radiotherapy were started at a gemcitabine dose of 600 mg/m 2 days 1 and 8 every 21 days. In the absence of dose-limiting toxicity, the gemcitabine dose was escalated 200 mg/m 2 per cycle to a maximum dose of 1000 mg/m 2 days 1 and 8. Patients were treated with decadron 4 mg orally twice daily, the day before, the day of, and the day after chemotherapy to prevent capillary leak syndrome. Patients were to have been assigned on the basis of HER-2 expression by immunohistochemistry with possible confirmation by fluorescence in situ hybridization to either chemotherapy alone or to combined chemotherapy and trastuzumab. We intended to treat the group with negative HER-2 expression with the combination of weekly docetaxel and gemcitabine alone. The group with HER-2 overexpression was to have been treated with chemotherapy in combination with trastuzumab. In the absence of measurable HER-2 expression in the first 18 patients and given the lack of improved response and survival for trastuzumab with chemotherapy over chemotherapy alone reported in the literature, we suspended the component of the trial that included trastuzumab and proceeded with chemotherapy alone in all enrollees.
Tumor measurements were obtained every two cycles. Patients with stable disease or response continued treatment up to six cycles, and at investigator discretion, in the absence of cumulative toxicity or disease progression, patients could continue treatment beyond six cycles. The study was open for accrual at Fox Chase Cancer Center and other medical centers participating in the Oncology Physicians Network, a clinical trials consortium in the Delaware Valley.
Statistical Design and Analysis
The primary objective was to assess the RR of the regimen determined by Response Evaluation Criteria in Solid Tumors. A two-stage design was used for this study. A proportion of patients with favorable response of less than 15% was considered to be of no interest. The new treatment would be of interest if the proportion of patients with favorable response proved to be 35% or higher. Thirty-four pa-tients were needed to test the null hypothesis: P Ͻ 0.15 against the alternative hypothesis: P Ͼ 0.35 with 13% significance and 95% power. The rationale for using the type I error larger than the type II is given in Rogatko and Litwin, JNCI 1996;88:462 Letter. The early stopping point was 17 patients. If only 0 to 1 favorable response were observed after 17 patients were accrued, then the null hypothesis would have been accepted and the trial terminated. If six or more patients with tumor response were observed when 17 evaluable patients were accrued, then the alternative hypothesis would be accepted and the trial terminated. The probability of early stopping under the null was 0.28 and under the alternative 0.59. If the trial progressed until 34 patients were evaluated and eight or more patients with favorable response were observed, then the null hypothesis would be rejected.
RRs were determined for all patients in the study as part of an intention to treat analysis, irrespective of the number of cycles. Confidence limits for the maximum likelihood estimate of the RR were determined using an exact calculation based on a two-stage design (Litwin). All patients were included in the survival analyses. The Kaplan-Meier productlimit method was used to estimate median EFS, which was determined as time from the start of treatment to either the progression of disease (PD) or the date of death in the absence of PD; patients were censored at date of last followup. Differences in EFS by gender, radiation, and ECOG status were also examined and assessed using the log-rank test. Overall survival including median and 1-year survival rates were determined as time from start of treatment to date of death; living patients were censored at date of last followup. All analyses were done using Statistical Analysis Software. The study protocol and consent forms were approved by research review committee and institutional review board before the study was initiated.
RESULTS

Enrollment
A total of 35 patients from two separate institutions were enrolled in the study, one more than the projected sample size of 34. An additional patient was recruited because one patient received only one cycle of treatment when a minimum of two were required for analysis. Following the "intention to treat" principle, all 35 patients were included in the analyses.
Patient Characteristics
Demographic characteristics are shown in Table 1 . The median time from initial diagnosis (TDx) to enrollment was 12.4 months (range ϭ 0.9 to 183.3 months). Median age was 61; there were no age limits. Men constituted 57% of enrollees; an identical percentage previously underwent irradiation. Median follow-up was 12.5 months.
Response to Treatment
A total of 170 cycles were administered to the 35 enrollees. The median number of cycles was 4 (range, 1-16). RRs were determined for all 35 patients (intention to treat cohort). None of the patients had a complete response; 8 had a partial response (RR ϭ 23%, 95% confidence interval ϭ 12 to 39%). Of the eight patients who responded, two patients had no PD at the last follow-up and six had experienced disease progression or had died.
Event-Free Survival and Overall Survival
The median event-free survival was 5.7 months. (Figure 1 ) At 12 months after the start of treatment, the event-free survival estimate was 37%. The median overall survival time was 12.5 months (Figure 1) . At 12 months, the overall survival rate was 51.4%. The 2-year survival was 31%. Four participants remain alive, with follow-up dates of January (n ϭ 2), February (n ϭ 1), and March (n ϭ 1) 2008.
Compliance with Treatment
Twelve patients (34%) completed at least six cycles of therapy and two to four cycles were given to 60% of patients. Four enrollees stopped treatment in the absence of disease progression or untoward toxicity after 6 (1 patient), 10 (2 patients), and 16 (1 patient) cycles. Of all 35 patients on study, the median time on treatment was 88 days (range, 34 -329 days).
Reasons for treatment discontinuation included disease progression in 17 patients, withdrawal or refusal in 3 patients, intercurrent comorbidity precluding continuation of therapy in 7 patients, need for palliative radiation therapy in 1 patient, and completion of treatment assignment in 4 patients. The details are in Table 2 .
Patient Characteristics and Event-Free Survival
Differences in event-free survival by gender, ECOG performance status, prior radiation therapy, time between TDx and start of treatment, and age were assessed using the log-rank test. There were no differences based on gender, prior radiation therapy, performance status, or age. Nevertheless, improved EFS correlated with longer time from TDx to the start of treatment: 13.7 months for TDx Ն12 months compared with 4.8 months for TDx Ͻ12 months (log-rank test P ϭ 0.031) (Figure 2 ).
HER-2 Expression Data
We were able to determine HER-2 expression in the first 18 patients; all proved negative. Among these individuals, four (22%) had partial response, eight (44%) had stable disease and six (33%) had PD on treatment. After 18 patients had been accrued, and it was determined that none had HER-2 expression, routine determination of HER-2 status Three (one with COPD, anemia, and pneumonia-one with hyponatremia, SAIDH, pneumonia, and change in mental status, and one with grade 2 neuropathy persisting Ͼ3 wk) Need for palliative radiation therapy One patient Intercurrent toxicity Seven patients: Ataxia and depression deemed possibly related, which proved intolerable to one patient Decrease in performance status deemed possibly related, in one patient Patient and physician decision in one patient Pneumonitis in two patients, in each case deemed definitely related Skin toxicity considered definitely related in one patient Leg edema deemed definitely related in one patient Completion of assigned treatment Four patients was abandoned, and the component of the trial integrating trastuzumab with gemcitabine and docetaxel was discarded.
Toxicity
Data for grades 3 and 4 toxicities that were felt to be possibly, probably, or definitely related to the study treatment are shown in Table 3 . There were no disease-related deaths. Hematological toxicity included 1 patient each with grade 3 anemia and thrombocytopenia, 15 patients with at least grade 3 neutropenia, and 6 patients with grade 4 neutropenia. There was no exclusion for the use of growth factor, but only two patients required G-cerebrospinal fluid, only one of whom had neutropenic fever. Six grade 3 and two grade 4 infections were observed on study. The infections were not related to study treatment and were treated with per standard medical care. None resulted in death.
DISCUSSION
We initiated a trial of weekly docetaxel schedule because of its reduced toxicity and similar efficacy compared with the more conventional every 3-week schedule. 4 Our study yielded a RR of 23%, median survival of 12.5 months, and event-free survival of 5.7 months. These results seem comparable to several other phase II studies using docetaxel and gemcitabine in combination as first-line therapy (Table  4) . This combination, despite its use in the second-line setting, did not cause severe toxicity; and there were no treatment-related deaths.
Compared with historic controls, survival in this phase II study compares favorably with the results of prior phase III studies. BR-21, for example, orchestrated through the NCI-C, compared single agent erlotinib to placebo and showed a RR of 8.9%, progression free survival of 2.2 months and median survival of 6.7 months for the erlotinib arm. 29 In a phase III trial comparing pemetrexed to docetaxel in patients with recurrent NSCLC, pemetrexed yielded a RR of 9.1%, median progression free survival of 2.9 months, and median survival of 8.3 months. Docetaxel yielded a RR of 8.8%, median progression of 2.9 months, and median survival of 7.9 months. 30 Whether the apparent improvement in outcome on our phase II effort reflects the inherent superiority of this regimen or instead represents selection bias or the effects of third and fourth line therapy is open to speculation. We do not have data on subsequent therapy and therefore cannot quantify the extent of exposure to other therapies including pemetrexed or erlotinib. This information would have been valuable in determining the impact of additional therapy in the survival of these patients. Moreover, the bulk of accrual came from a single center, so unintentional selection bias may have influenced outcomes. But it should be noted that there were no competing second-line trials either at Fox Chase Cancer Center or in Oncology Physicians Network at the time of this study. In addition, all of these patients had intact performance status (0 or 1) after initial chemotherapy and were very likely in better shape clinically when compared with those enrolled on other trials. Over 30% of those accrued to the BR-21 effort, for example, were PS 2 or 3, and about 11% enrolled on the phase III trial comparing docetaxel with Pemetrexed were PS 2. In addition, we showed that time from TDx to start of treatment had a direct bearing on EFS: 13.7 months versus 4.8 months for Ն12 months elapsed from diagnosis versus Ͻ12 months. (P ϭ 0.037). This observation suggests some degree of cross-resistance in those whose disease has progressed quickly either during or immediately after prior therapy.
Which therapy to choose in the second-line setting and when to integrate targeted agents or chemotherapeutics remain unanswered. Recent phase III trials seem to suggest that both chemotherapy and targeted therapies yield similar efficacy, albeit with significant differences in toxicity. Recent studies with targeted combinations have yielded improved RRs and reasonably acceptable toxicity profiles. This is exemplified by the Erlotinib and Bevacizumab doublet, which yielded a RR of 18% and 1-year survival rate of 57% compared with a RR of 12% and 1-year survival rate of 33% with chemotherapy alone. 31 The natural concern with combined chemotherapy is toxicity, but if a novel combination can yield higher RRs and longer survival, many clinicians are willing to accept increased levels of toxicity as long as the regimen remains tolerable. A nonplatinum doublet is a viable option in good performance status patients who have had prior platinum exposure and it may ultimately prove to be the regimen of choice when treating recurrent disease after adjuvant chemotherapy with a platinum doublet, which has emerged as a standard of care based on recent trials. 32, 33, 34 We conclude that the nonplatinum doublet of docetaxel and gemcitabine in the second-line setting is feasible and capable of producing a reasonable RR and prolonged EFS and overall survival. But, it still begs the question as to how this combination would compare with either the constituent single agents or new therapeutic combinations (erlotinib, pemetrexed, or bevacizumab). Given the results observed in our effort, a phase III trial comparing the weekly regimen of gemcitabine and docetaxel to standard docetaxel alone or to other second-line agents alone should be considered. Unfortunately, the appetite for such an effort in the new era of targeted therapy is very likely limited.
